ACRON GENOMICS bricht gerade aus - 500 Beiträge pro Seite

[WissenMacht]

Der Zukünftige Marktführer:
ACRON GENOMICS

Nanobiotechnologieunternehmen mit revolutionärer Produktpipeline

In der aktuellen Ausgabe des PENNYSTOCK REPORTs empfehlen die Analysten die Acrongenomics Inc. (WKN: A0B9TS / ISIN: US0050151028), ein Biotechnologie-Unternehmen, das spezialisiert ist auf die Entwicklung und den Vertrieb von innovativen Diagnostiklösungen.


Neo-EpCAM Cancer Detection Kit

Dieses Produkt wird zukünftig für die Erkennung von Krebs am Ausgangspunkt genutzt werden. Es ermöglicht, die Ergebnisse sensitiver und genauer zu ermitteln. Die neue Technologie verringert die Testdauer um bis zu 75% und senkt die Laborkosten deutlich. Dies bedeutet einen besseren Service sowie aussagekräftigere Ergebnisse.


Die Nano-JETA™ Plattform

Diese Plattform hat das Potenzial, den molekularen Diagnostiksektor zu revolutionieren und neu zu definieren. Die Ergebnisse werden im Schnitt zehnmal so schnell ermittelt als bei allen herkömmlichen PCR-Systemen. Im Gegensatz zu anderen gleichartigen Tests werden weniger Schritte und weniger Enzymmaterial für die Durchführung der Tests benötigt. Somit können die Ergebnisse bis zu viermal schneller ausgelesen werden.


Strategische Allianzen

Acrongenomics hat eine strategische Allianz mit Eurogenet Laboratories geschlossen. Im Vordergrund steht für Acrongenomics die Qualitätskontrolle, um ein zuverlässiges, sicheres System mit einer hohen Performance zu schaffen.


Fazit:

Sollte Acrongenomics im nächsten Schritt die kommerzielle Produktion verwirklichen, wäre hier ein erhebliches Marktpotenzial zu erschließen und eine zukünftige Marktführerschaft nicht ausgeschlossen. Wenn sich die Produkte am Markt durchsetzen, wären Kurse im zweistelligen Bereich vertretbar. Die Analysten des PENNYSTOCK REPORTs sehen ihr erstes Kursziel bei 5 Euro.


Lesen Sie kostenlos die komplette Analyse zur Acrongenomics Inc. und das Interview mit dem President und CSO auf www.pennystockreport.de
Autor: PennyStock, 08:30 31.03.0


strong buy

[WissenMacht]

Acrongenomics Inc. Announcement
Friday March 11, 9:30 am ET

ATHENS, Greece--(BUSINESS WIRE)--March 11, 2005--Acrongenomics Inc. (OTCBB:AGNM) a Research and Development company focused in the field of nanobiotechnology is exploring future prospects by evaluating the technology behind existing implementations of PCR, ELISA and Real Time PCR.
According to our market research, current applications reveal certain limitations, including problems with efficiency and cost effectiveness. Acrongenomics Inc. endeavors to overcome these limitations by introducing nanotechnology into molecular biology. Nanotechnology is beginning to generate substantial new insights into how biological systems function and is believed to hold potential advances in both the pharmaceuticals and health care industries.

Acrongenomics Inc. believes that its first application, the Neo-EpCAM(TM) Cancer detection kit provides enhanced performance as a result of its ongoing Nano-JETA(TM) platform, which combines nanotechnology with molecular biology and applies in PCR, enzyme reactions - including universal ELISA Detection Systems - and Real Time PCR.

In total, 97 different tissue samples from patients suffering from laryngeal cancer, and 82 different tissue samples from patients suffering from breast cancer were used for standardization, evaluation, validation and characterization of our Neo-EpCAM(TM) cancer detection kit. A characterization and evaluation report for Neo-EpCAM(TM) has been completed in universal PCR and ELISA.

By advancing our know-how in nanotechnology, we managed to apply our Nano-JETA(TM) platform on the detection of more markers and viral targets such as Neo-EpCAM(TM), HER1, HER2, HER3, and HER4, with the incorporation of the appropriate primers. A characterization and evaluation report has been completed in PCR and ELISA.

750 tests were performed in colon and breast cancer samples
750 tests were performed in colon and laryngeal cancer samples
250 tests were also performed in breast and laryngeal cancer samples


In essence, Nano-JETA(TM) Platform shows a potential in eliminating all known limitations of current technologies. These developments led to the reshaping of both Conventional PCR and ELISA, to Nano-JETA(TM) PCR, and Universal Nano-JETA(TM) ELISA respectively without compromising sensitivity, specificity and reliability.

Realizing the potential applications of our Nano-JETA(TM) Platform is of crucial importance in understanding its diversity. There is a large number of possible permutations waiting to be explored, and therefore Acrongenomics has evolved Nano-JETA(TM) Platform in Real-Time PCR application for "markers" such as EpCAM, HER1, HER2, and vEGF by conducting clinical validation trials in 400 samples of breast, colon, lung and ovarian cancer anticipating completion by the end of March 2005. Preliminary indications reveal precision, accuracy, specificity and reproducibility.

By evolving our proprietary technology, we have currently achieved a typical Real-Time PCR in 47 seconds without compromising sensitivity, specificity and reliability.

Nano-JETA(TM) platform as an application for Real Time PCR uses common Real Time PCR equipment revealing qualitative results even from the first cycle reaching maximum performance at the eighth cycle.

In addition, with such achievements and in order to strengthen our position, we have decided to conduct independent validation studies in U.S.

Molecular diagnostic testing is the fastest-growing segment of the in vitro diagnostics industry. The last four years, clinical market for molecular diagnostic products has increased from $1 billion in 2000 to 2,8 billion in 2004 and sales are expected to exceed $5 billion by 2008 (Biotechnology Associates). So profitable is the molecular diagnostics market that pharmaceutical and biotechnology companies are highly focused in developing tests that can be used to guide prescribing, and individualize patient treatment.



www.acrongen.com

[WissenMacht]

Guten Morgen.
Aufwachen

[WissenMacht]

alles einsteigen bzw aufspringen.

strong buy.

[WissenMacht]

[WissenMacht]

hehe

[Wuscher]

ACRONGENOMICS Inc. SHOWS RESULTS FROM ITS FIRST CLINICAL VALIDATION STUDY ON Nano-JETA™ PLATFORM
May 6, 2005 10:17 AM Eastern

ATHENS, Greece-May 04, 2005--Acrongenomics Inc. (OTCBB:AGNM) a Research and Development company focusing in the field of nanobiotechnology has managed to reshape key IVD molecular applications such as PCR, ELISA and Real Time PCR through its Nano-JETA™ technology platform, by integrating nanotechnology into molecular biology.

Acrongenomics Inc. recently conducted a clinical validation study at EuroGENET Laboratories SA to further establish its Nano-JETA™ technology platform in regards to Real Time PCR application, the Nano-JETA™ Real Time PCR.

The objectives of the study were:

a) to validate the Nano-JETA™ Real Time PCR via the detection of Ep-CAM gene and ß-actin (internal control) in peripheral blood of patients suffering from breast and colon cancer (patients were histologically and cytologically verified), and

b) to evaluate the Nano-JETA™ technology platform in comparison to conventional Real Time PCR methodology for Ep-CAM and ß-actin respectively in regards to stability, sensitivity, specificity and reproducibility.

The study was designed intentionally incorporating the most difficult parameters such as blind control, multi-centre clinical validation study, with variant and unidentified patient status (primary or metastatic status, follow up or on treatment)

The original number of patient samples was 250 but according to EuroGENET Labs Quality Control acceptance criteria, only 236 patient samples qualified as appropriate for participating in the study. The remaining 14 samples were rejected. Therefore, RNA was extracted from fresh blood samples of 236 patients suffering from breast and colon cancer. cDNA was produced according to both Nano-JETA™ and conventional cDNA protocols.

Conventional Real Time PCR and Nano-JETA™ Real Time PCR were performed for Ep-CAM and ß-actin. The average cycles required for Real Time PCR and Nano-JETA™ Real Time PCR completion were 45 and 13 respectively. Furthermore, the total reaction volume required for Real Time PCR and Nano-JETA™ Real Time PCR was 25µl and 8µl respectively.

Research results revealed that in the case of ß-actin (internal control) both protocols exhibited 100% specificity.
ß-actin was detectable from the 16th to 18th cycle when using common Real-Time PCR, while only 1 single cycle was required with Nano-JETA™ Real-Time PCR.

In regards to sensitivity, common Real-Time PCR detected 104 cancer cells, while requiring 22 to 32 cycles. In contrast, Acrongenomics’ Nano-JETA™ Real-Time PCR exhibited sensitivity of 10² cancer cells, with the use of 1 single cycle.

By using common Real-Time PCR, Ep-CAM was detected in 28 samples out of 236 (11,9% positive) and it was not found in 208 samples (88,1% negative) showing sensitivity of 104 cancer cells as noted before.

On the other hand, by using Nano-JETA™ Real-Time PCR, Ep-CAM was detected in those same 28 samples – but it was also detected in 22 additional samples (21,2%). It was not detected in 186 samples out of 236 (78,8% negative), exhibiting sensitivity of 10² cancer cells. This was due to the fact that Nano-JETA™ Real-Time PCR is one hundred times more sensitive than conventional Real Time PCR.

Acrongenomics believes that the capabilities and performance of the Nano-JETA™ technology platform developed by Acrongenomics Inc. could be regarded as a breakthrough application in the diagnostic market for stability, sensitivity, specificity and reproducibility.

[Ma.Ro]

[posting]16.303.595 von WissenMacht am 05.04.05 20:49:07[/posting]Seid Deiner Eröffnung hier ca. 40% plus


RESPEKT

[WissenMacht]

thx

wünsche einen schönen Feiertag

WiMa